| Literature DB >> 31576175 |
Hui Xie1, Gang Li1, Kangkang Liu1, Zhun Wang1, Zhiqun Shang1, Zihao Liu1, Zhilei Xiong1, Changyi Quan1, Yuanjie Niu1.
Abstract
PURPOSE: In recent years, there has been an increase in the incidence of small renal masses (SRMs) and nephrectomy was the standard management of this disease in the past. Currently, the use of active surveillance has been recommended as an alternative option in the case of some patients with SRMs due to its heterogenicity. However, limited studies focused on the regarding risk stratification. Therefore, in the current study, we developed a nomogram for the purpose of predicting the presence of high-grade SRMs on the basis of the patient information provided (clinical information, hematological indicators, and CT imaging data). PATIENTS AND METHODS: A total of 329 patients (consisting of development and validation cohort) who had undergone nephrectomy for SRMs between January 2013 and May 2016 retrospectively were recruited for the present study. All preoperative information, including clinical predictors, hematological indicators, and CT predictors, were obtained. Lasso regression model was used for data dimension reduction and feature selection. Multivariable logistic regression analysis was applied for the establishment of the predicting model. The performance of the nomogram was assessed with respect to its calibration and discrimination properties and externally validated.Entities:
Keywords: CT; SRMs; nomogram; renal cell carcinoma; small renal masses; tumor histology
Year: 2019 PMID: 31576175 PMCID: PMC6767976 DOI: 10.2147/CMAR.S186914
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
Figure 1Predictive features on CT imaging as assessed: (A and B) exophytic properties; (C) necrosis and well-defined tumor contour; (D) ill-defined tumor contour; and (E) collecting system oppression.
Demographic and histopathological information on development and validation cohort
| Characteristic | Development cohort | Validation cohort |
|---|---|---|
| Histopathological type, no. (%) | ||
| Clear cell RCC | 141(65.0) | 77(68.8) |
| Papillary RCC type Ⅰ | 24(11.1) | 10(8.9) |
| Papillary RCC type Ⅱ | 5(2.3) | 2(1.8) |
| Chromophobe RCC | 18(8.3) | 8(7.1) |
| Other | 5(2.3) | 2(1.8) |
| Oncocytoma | 15(6.9) | 8(7.1) |
| Angiomyolipoma | 9(4.1) | 5(4.5) |
| Nephrectomy, no. (%) | ||
| Partial | 156(71.9) | 76(67.9) |
| Radical | 61(28.1) | 36(32.1) |
| Fuhrman grade, no. (%) | ||
| Low grade | 153(70.5) | 81(72.3) |
| High grade | 64(29.5) | 31(27.7) |
Abbreviation: RCC, renal cell carcinoma.
Characteristics of patients in the development and validation cohort
| Characteristic | Development cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|
| High grade | Low grade | High grade | Low grade | |||
| Age, mean ± SD, years | 56.58±12.68 | 56.07±10.39 | 0.580 | 55.06±11.14 | 58.73±11.10 | 0.267 |
| Gender, no. (%) | ||||||
| Male | 38(59.4) | 107(69.9) | 0.155 | 26(83.9) | 59(72.8) | 0.324 |
| Female | 26(40.6) | 46(30.1) | 5(16.1) | 22(27.2) | ||
| BMI, mean ± SD | 24.64±2.41 | 25.37±2.99 | 0.064 | 24.72±2.58 | 25.15±3.27 | 0.718 |
| Clinical presentation | ||||||
| Symptomatic | 20(31.3) | 31(20.3) | 0.113 | 10 (32.3) | 18(22.2) | 0.331 |
| Asymptomatic | 44(68.7) | 122(79.7) | 21 (67.7) | 63 (77.8) | ||
| ALC, mean ± SD, 109/L | 1.88±0.39 | 2.05±0.55 | 0.154 | 1.73±0.43 | 1.90±0.53 | 0.157 |
| NLR, mean ± SD | 2.09±0.72 | 1.90±0.57 | 0.064 | 2.24±0.70 | 2.10±1.84 | 0.055 |
| Size, mean ± SD, cm | 3.44±0.49 | 2.90±0.81 | <0.001 | 3.40±0.58 | 2.90±0.68 | <0.001 |
| Necrosis, no. (%) | ||||||
| Positive | 40 (62.5) | 43 (28.1) | <0.001 | 16 (51.6) | 32 (39.5) | 0.289 |
| Negative | 24 (37.5) | 110 (71.9) | 15 (48.4) | 49 (60.5) | ||
| Exophytic properties, no. (%) | ||||||
| Exogenous | 28 (43.8) | 96 (62.7) | 0.011 | 10(32.3) | 45 (55.6) | 0.035 |
| Endogenous | 36 (56.2) | 57 (37.3) | 21 (67.7) | 36 (44.4) | ||
| Tumor contour, no. (%) | ||||||
| Well-defined | 14 (21.9) | 93 (60.8) | <0.001 | 8 (25.8) | 47 (58.0) | 0.003 |
| Ill-defined | 50 (78.1) | 60 (39.2) | 23 (74.2) | 34 (42.0) | ||
| Collection system oppression, no. (%) | ||||||
| Positive | 43 (67.2) | 27 (17.6) | <0.001 | 24 (77.4) | 14 (17.3) | <0.001 |
| Negative | 21 (32.8) | 126 (82.4) | 7 (22.6) | 67 (82.7) | ||
Note: P-value was derived from the Wilcoxon rank sum test and Fisher’s exact test.
Abbreviations: ALC, absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio.
Figure 2Feature selection on the basis of the least absolute shrinkage and selection operator (LASSO) binary logistic regression model. (A) The tuning parameter (λ) in the LASSO model was chosen to be 10 cross-validations with a minimum standard. The area under the receiver operating characteristic (AUC) curve was plotted versus log (λ). By using the minimum standard and the 1 standard error of the minimum standard (1-SE standard), dotted vertical lines were drawn at the optimum value. The value of λ was 0.063 and the log (λ) was −2.76 (1-SE standard) according to 10-fold cross-validation. (B) LASSO coefficient profile for 14 features. A coefficient profile plot was generated for the log (λ) sequence. A vertical line was drawn at the value selected using 10-fold cross-validation, where the best (λ) resulted in 4 non-zero coefficients.
Risk features for high-grade small renal mass
| Intercept and variable | β | Odds ratio (95% CI) | |
|---|---|---|---|
| Intercept | −5.112 | 0.006 | |
| Size | 0.820 | 2.270 (1.158–4.451) | 0.017 |
| Necrosis | 1.736 | 5.673 (2.399–13.411) | <0.001 |
| Exophytic properties | −1.545 | 0.213 (0.086–0.529) | 0.001 |
| Tumor contour | 1.377 | 3.962 (1.639–9.574) | 0.002 |
| Collection system oppression | 1.798 | 6.038 (2.760–13.212) | <0.001 |
Note: β is the regression coefficient.
Figure 3Nomogram for evaluating the risk of high-grade tumor histological subtype. Points were assigned by plotting a straight line from the proper spot on each predictor level up to the “Points” level; sum points achieved for each predictor and locate this sum on “Total Points” axis, then drawn a straight line down to determine the corresponding probability of high-grade tumor histological subtype.
Figure 4Calibration curves of the nomogram in the development (A) and validation (B) cohort. Calibration curves depict the calibration of final model based on the agreement between the predicted risk of high-grade histological subtype and the observed outcome of high-grade histological subtype. The solid line represents the performance of the nomogram, and the position which was closer to the diagonal dashed line represents a better prediction.
Figure 5Receiver operator characteristics (ROC) curve developed from patients of development (A) and validation (B) cohort when nomogram was used to predict high-grade tumor vs low-grade tumor histological subtype.
Abbreviation: AUC, area under the curve.